ATE304846T1 - Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen - Google Patents

Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen

Info

Publication number: ATE304846T1
Authority: AT; Austria
Prior art keywords: prevention; treatment; ibuprofen; organs; rejection reactions
Prior art date: 2001-02-02

Application number

AT02719742T

Other languages

English (en)

Inventor

Riccardo Bertini

Francesco Colotta

Roberto Novellini

Original Assignee

Dompe Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-02

Filing date

2002-01-30

Publication date

2005-10-15

2002-01-30 Application filed by Dompe Spa filed Critical Dompe Spa

2005-10-15 Application granted granted Critical

2005-10-15 Publication of ATE304846T1 publication Critical patent/ATE304846T1/de

Links

238000006243 chemical reaction Methods 0.000 title abstract 3
URZONQSEPBBTSB-HNCPQSOCSA-N methanesulfonamide;(2r)-2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound CS(N)(=O)=O.CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 URZONQSEPBBTSB-HNCPQSOCSA-N 0.000 title abstract 3
230000002265 prevention Effects 0.000 title abstract 3
210000000056 organ Anatomy 0.000 title abstract 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
208000027418 Wounds and injury Diseases 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
210000003734 kidney Anatomy 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

AT02719742T 2001-02-02 2002-01-30 Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen ATE304846T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2001MI000206A ITMI20010206A1 (it)	2001-02-02	2001-02-02	Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PCT/EP2002/000946 WO2002062330A2 (en)	2001-02-02	2002-01-30	Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Publications (1)

Publication Number	Publication Date
ATE304846T1 true ATE304846T1 (de)	2005-10-15

Family

ID=11446717

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02719742T ATE304846T1 (de)	2001-02-02	2002-01-30	Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen

Country Status (26)

Country	Link
US (1)	US7560487B2 (de)
EP (1)	EP1355641B1 (de)
JP (1)	JP2004517948A (de)
KR (1)	KR100857898B1 (de)
CN (1)	CN1561205A (de)
AT (1)	ATE304846T1 (de)
AU (1)	AU2002250869B2 (de)
BR (2)	BRPI0206804B1 (de)
CA (1)	CA2432432C (de)
CZ (1)	CZ303665B6 (de)
DE (1)	DE60206245T2 (de)
DK (1)	DK1355641T3 (de)
EE (1)	EE05233B1 (de)
ES (1)	ES2248541T3 (de)
HU (1)	HU229070B1 (de)
IL (1)	IL157180A (de)
IT (1)	ITMI20010206A1 (de)
MX (1)	MXPA03006686A (de)
NO (1)	NO334285B1 (de)
NZ (1)	NZ526655A (de)
PL (1)	PL215109B1 (de)
PT (1)	PT1355641E (de)
RU (1)	RU2257895C2 (de)
SK (1)	SK287632B6 (de)
WO (1)	WO2002062330A2 (de)
ZA (1)	ZA200304861B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE347883T1 (de) *	2004-03-25	2007-01-15	Dompe Pha R Ma Spa Res & Mfg	Verwendung von n-(2-aryl-propionyl)-sulfonamiden zur behandlung von rückenmarkverletzungen
WO2006121995A2 (en)	2005-05-09	2006-11-16	Tap Pharmaceutical Products, Inc.	Methods for treating nephrolithiasis
BRPI0718611A2 (pt) *	2006-11-13	2014-02-25	Takeda Pharmaceuticals North America Inc	Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.
EP2308485A1 (de)	2009-10-06	2011-04-13	Dompé S.p.a.	Sulfonamide zur Diabetesprävention
EP2308484A1 (de) *	2009-10-06	2011-04-13	Dompé S.p.a.	Hemmer von CXCRL1/2 als Adjuvanzien bei der Transplantation von Langerhans-Zellen
WO2012033941A1 (en)	2010-09-10	2012-03-15	Takeda Pharmaceuticals North America, Inc.	Methods for concomitant treatment of theophylline and febuxostat
US10046002B2 (en)	2013-08-02	2018-08-14	Syntrix Biosystems Inc.	Method for treating cancer using chemokine antagonists
US10561676B2 (en) *	2013-08-02	2020-02-18	Syntrix Biosystems Inc.	Method for treating cancer using dual antagonists of CXCR1 and CXCR2
CN110431424B (zh) *	2017-03-15	2023-04-07	诺码锐思股份公司	用于确定肾排斥风险的标志物组的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4879283A (en) *	1985-10-03	1989-11-07	Wisconsin Alumni Research Foundation	Solution for the preservation of organs
RU2008901C1 (ru) *	1991-03-29	1994-03-15	Донецкий государственный медицинский институт им.М.Горького	Способ фармакологической защиты децентрализованной почки
NZ256328A (en) *	1992-09-17	1997-06-24	Amgen Boulder Inc	Pharmaceutical compositions of interleukin-1 inhibitor and non-ionic surfactant or viscosity enhancer
IL110296A (en) *	1993-07-16	1999-12-31	Smithkline Beecham Corp	Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JPH08231413A (ja) *	1994-12-29	1996-09-10	Mochida Pharmaceut Co Ltd	臓器障害に基づく疾患の予防・治療剤
IT1303249B1 (it) *	1998-10-23	2000-11-06	Dompe Spa	Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US6355682B1 (en) *	2001-05-11	2002-03-12	Assa Weinberg	Treatment of acute renal failure by administration of N-acetylcysteine

2001
- 2001-02-02 IT IT2001MI000206A patent/ITMI20010206A1/it unknown
2002
- 2002-01-30 HU HU0303024A patent/HU229070B1/hu not_active IP Right Cessation
- 2002-01-30 EP EP02719742A patent/EP1355641B1/de not_active Expired - Lifetime
- 2002-01-30 CN CNA028042263A patent/CN1561205A/zh active Pending
- 2002-01-30 AU AU2002250869A patent/AU2002250869B2/en not_active Ceased
- 2002-01-30 KR KR1020037009714A patent/KR100857898B1/ko not_active Expired - Fee Related
- 2002-01-30 CZ CZ20032095A patent/CZ303665B6/cs not_active IP Right Cessation
- 2002-01-30 MX MXPA03006686A patent/MXPA03006686A/es active IP Right Grant
- 2002-01-30 WO PCT/EP2002/000946 patent/WO2002062330A2/en not_active Ceased
- 2002-01-30 DE DE60206245T patent/DE60206245T2/de not_active Expired - Lifetime
- 2002-01-30 PL PL363576A patent/PL215109B1/pl unknown
- 2002-01-30 CA CA002432432A patent/CA2432432C/en not_active Expired - Fee Related
- 2002-01-30 SK SK973-2003A patent/SK287632B6/sk not_active IP Right Cessation
- 2002-01-30 BR BRPI0206804A patent/BRPI0206804B1/pt unknown
- 2002-01-30 NZ NZ526655A patent/NZ526655A/en not_active IP Right Cessation
- 2002-01-30 BR BR0206804-4A patent/BR0206804A/pt not_active IP Right Cessation
- 2002-01-30 PT PT02719742T patent/PT1355641E/pt unknown
- 2002-01-30 ES ES02719742T patent/ES2248541T3/es not_active Expired - Lifetime
- 2002-01-30 EE EEP200300340A patent/EE05233B1/xx not_active IP Right Cessation
- 2002-01-30 DK DK02719742T patent/DK1355641T3/da active
- 2002-01-30 RU RU2003126600/15A patent/RU2257895C2/ru not_active IP Right Cessation
- 2002-01-30 JP JP2002562337A patent/JP2004517948A/ja active Pending
- 2002-01-30 AT AT02719742T patent/ATE304846T1/de active
2003
- 2003-01-30 US US10/250,465 patent/US7560487B2/en not_active Expired - Fee Related
- 2003-06-23 ZA ZA200304861A patent/ZA200304861B/en unknown
- 2003-07-18 NO NO20033273A patent/NO334285B1/no not_active IP Right Cessation
- 2003-07-31 IL IL157180A patent/IL157180A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP0303024A2 (hu)	2003-12-29
DE60206245T2 (de)	2006-06-14
PL215109B1 (pl)	2013-10-31
BRPI0206804B1 (pt)	2018-09-25
HU229070B1 (hu)	2013-07-29
NZ526655A (en)	2005-02-25
EP1355641B1 (de)	2005-09-21
SK9732003A3 (en)	2003-11-04
JP2004517948A (ja)	2004-06-17
CN1561205A (zh)	2005-01-05
CZ303665B6 (cs)	2013-02-20
CA2432432A1 (en)	2002-08-15
NO20033273D0 (no)	2003-07-18
CA2432432C (en)	2008-03-25
DK1355641T3 (da)	2005-10-17
EE200300340A (et)	2003-10-15
WO2002062330A3 (en)	2003-04-03
US7560487B2 (en)	2009-07-14
ES2248541T3 (es)	2006-03-16
SK287632B6 (sk)	2011-04-05
RU2257895C2 (ru)	2005-08-10
AU2002250869B2 (en)	2006-10-19
US20040102520A1 (en)	2004-05-27
WO2002062330A2 (en)	2002-08-15
EP1355641A2 (de)	2003-10-29
KR20030074725A (ko)	2003-09-19
CZ20032095A3 (en)	2004-05-12
NO20033273L (no)	2003-07-18
NO334285B1 (no)	2014-01-27
DE60206245D1 (de)	2006-02-02
EE05233B1 (et)	2009-12-15
MXPA03006686A (es)	2004-05-31
ITMI20010206A1 (it)	2002-08-02
BR0206804A (pt)	2004-02-03
IL157180A (en)	2009-06-15
KR100857898B1 (ko)	2008-09-10
HUP0303024A3 (en)	2005-07-28
ZA200304861B (en)	2004-06-30
PT1355641E (pt)	2005-11-30
PL363576A1 (en)	2004-11-29
RU2003126600A (ru)	2005-02-27

Legal Events

Date

Code

Title

Description

2006-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1355641

Country of ref document: EP

2007-09-15

EEIH

Change in the person of patent owner

Publication	Publication Date	Title
DE69508192D1 (de)	1999-04-15	Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
BG106825A (en)	2003-02-28	Substituted oxazolidinones and their use in the field of blood coagulation
DE60118604D1 (de)	2006-05-18	Photosensibilisator-enthaltende lagerungslösung zur inaktivierung von biologischen verunreinigungen
ATE442142T1 (de)	2009-09-15	Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE399782T1 (de)	2008-07-15	Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
EA200100154A1 (ru)	2001-08-27	Бензоциклогептены, способ их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
DE60032795D1 (de)	2007-02-15	Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE357438T1 (de)	2007-04-15	1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE69914756D1 (de)	2004-03-18	Verwendung von isoosmotischen salzlösungen zur verhütung von entzündungen
ATE412646T1 (de)	2008-11-15	Zur behandlung von schmerzen geeignete therapeutische mittel
ATE304846T1 (de)	2005-10-15	Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen
DE69617005D1 (de)	2001-12-20	2-amino-benzoxazinone zur behandlung von viralen infektionen
DE60313356D1 (de)	2007-05-31	Verwendungvon dextransulfat zur behandlung von ibmir
NO972065L (no)	1997-05-05	Lagringsstabil vannopplösning for infusjon inneholdende en trombininhibitor
DE60131968D1 (de)	2008-01-31	PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE50100833D1 (de)	2003-11-27	Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE344662T1 (de)	2006-11-15	Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DE602004022783D1 (de)	2009-10-08	Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
ATE521344T1 (de)	2011-09-15	Calciumsalze zur behandlung von psoriasis, dermatitis und schuppen
ATE232739T1 (de)	2003-03-15	Protein c zur behandlung von sichelzellanämie und thalassämie
DE69930419D1 (de)	2006-05-11	Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE423780T1 (de)	2009-03-15	Makrozyclen zur behandlung von krebserkrankungen
ATE464042T1 (de)	2010-04-15	Verwendung von neboglamine zur behandlung von schizophrenie
DE69832796D1 (de)	2006-01-19	Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
ATE384527T1 (de)	2008-02-15	Verwendung von tolperison zur behandlung von spasmen von organen, die im wesentlichen aus glatter muskulatur aufgebaut sind.